RxSight (RXST) Cash & Current Investments (2020 - 2026)

RxSight's Cash & Current Investments history runs 7 years deep, the most recent figure standing at $418.2 million for Q1 2026.

• Quarterly Cash & Current Investments fell 2.89% year-over-year to $418.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $418.2 million (down 2.89% YoY) and the FY2025 annual result came in at $436.3 million, up 83.91% from the prior year.
• Cash & Current Investments was $418.2 million for Q1 2026 at RxSight, down from $436.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $442.0 million in Q2 2024 and bottomed at $143.8 million in Q1 2022.
• A 5-year average of $300.9 million and a median of $253.9 million in 2023 frame the typical range for Cash & Current Investments.
• Peak annual rise in Cash & Current Investments reached 187.61% in 2022, while the deepest fall reached 32.11% in 2022.
• RxSight's Cash & Current Investments stood at $199.8 million in 2022, then grew by 22.49% to $244.7 million in 2023, then declined by 3.05% to $237.2 million in 2024, then soared by 83.91% to $436.3 million in 2025, then dropped by 4.14% to $418.2 million in 2026.
• Business Quant data shows RXST's Cash & Current Investments at $418.2 million in Q1 2026, $436.3 million in Q4 2025, and $425.4 million in Q3 2025.